This is a working overview of Dihexa, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-10 and is reviewed periodically as new material appears.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
=== Disputes with other politicians === In October 2023, Ford publicly stated that MPP Sarah Jama had a "long and well-documented history of antisemitism" and "hateful views", and that she "publicly support[ed] the rape and murder of innocent Jewish people," and called for her to resign. In response, Jama served Ford's office a cease and desist letter and threatened to sue him for libel. In April 2024, Doug Ford called for the reversal of the Speaker's ban on wearing keffiyeh in the legislature, which was imposed after an unidentified MPP complained about Sarah Jama donning a Palestinian keffiyeh at the start of the Gaza war. The motion to overrule the ban did not receive unanimous consent and remained in effect. In August 2026, it was reported that Ford's Progressive Conservative Party had sent a party official to follow Ontario Liberal Party leader Bonnie Crombie while she vacationed in Jamaica shortly after her election in 2023.
Vacutainer tubes may contain additional substances that preserve blood for processing in a medical laboratory. Using the wrong tube may make the blood sample unusable for the intended purpose. These additives are typically thin film coatings applied using an ultrasonic nozzle. The additives may include anticoagulants (EDTA, sodium citrate, heparin) or a gel with density between those of blood cells and blood plasma. Additionally, some tubes contain additives that preserve certain components of or substances within the blood, such as glucose. When a tube is centrifuged, the materials within are separated by density, with the blood cells sinking to the bottom and the plasma or serum accumulating at the top. Tubes containing gel can be easily handled and transported after centrifugation without the blood cells and serum mixing.
== Research contributions == Balalaie's research focuses on several areas of organic chemistry, including environmentally friendly synthetic methods and pharmaceutical applications. His research group has worked on the development of multicomponent reactions (MCRs), particularly for the synthesis of heterocyclic compounds. His work in this area has included the use of zeolite catalysts for the preparation of tetrasubstituted imidazoles and other heterocycles. His research has also involved developing synthetic routes for several active pharmaceutical ingredients (APIs). Compounds published by his group include: Zoledronic acid, Gabapentin, Deferasirox and Pantoprazole. In peptide synthesis, Balalaie's work has included the synthesis of therapeutic peptides such as triptorelin, leuprolide, octreotide, and oxytocin. His group has also designed cyclopeptides containing heterocyclic structures (imidazole, thiazole, oxazole) intended to serve as potential anticancer agents. His book "Peptide Chemistry in Persian" was recognized as a winner of the Iran Book of the Year Award in 1399 (2020).
Sources: en.wikipedia.org
Curium was first intentionally synthesized, isolated and identified in 1944, at University of California, Berkeley, by Glenn T. Seaborg, Ralph A. James, and Albert Ghiorso. In their experiments, they used a 60-inch (150 cm) cyclotron. Curium was chemically identified at the Metallurgical Laboratory (now Argonne National Laboratory), University of Chicago. It was the third transuranium element to be discovered even though it is the fourth in the series – the lighter element americium was still unknown. The sample was prepared as follows: first plutonium nitrate solution was coated on a platinum foil of ~0.5 cm2 area, the solution was evaporated and the residue was converted into plutonium(IV) oxide (PuO2) by annealing. Following cyclotron irradiation of the oxide, the coating was dissolved with nitric acid and then precipitated as the hydroxide using concentrated aqueous ammonia solution. The residue was dissolved in perchloric acid, and further separation was done by ion exchange to yield a certain isotope of curium. The separation of curium and americium was so painstaking that the Berkeley group initially called those elements pandemonium (from Greek for all demons or hell) and delirium (from Latin for madness). 242Cm was made in July–August 1944 by bombarding 239Pu with α-particles to produce curium with the release of a neutron:
=== Skin and circulation === Rattlesnakes, like other members of the Squamata order, have a circulatory system that is powered by a three-chambered heart composed of two atria and one ventricle. The right atrium receives deoxygenated blood from veins coming from the systemic circuit. The left atrium receives oxygenated blood from the lungs in the pulmonary circuit and pumps it to the ventricle and through the systemic circuit via capillaries and arteries. Rattlesnake skin has a set of overlapping scales that cover the entire body, providing protection from a variety of threats, including dehydration and physical trauma. The typical rattlesnake, genus Crotalus, has the top of its head covered with small scales, except, with a few species, a few crowded plates directly over the snout. The skin of snakes is highly sensitive to contact, tension, and pressure; they are capable of feeling pain. An important function of the skin is the sensation of changes in air temperature, which can guide the snakes towards warm basking/shelter locations. All snakes are ectotherms. To maintain a stable body temperature, they exchange heat with their external environments. Snakes often move into open, sunny areas to absorb heat from the sun and warmed earth, a behavior known as basking. Nerves in the skin regulate the flow of blood into the veins near the surface. The skin of rattlesnakes is intricately patterned in a manner that camouflages them from their predators.
This could be due to their shorter generation time, higher metabolic rate, increased population structuring, increased rate of speciation, or smaller body size. When studying ancient events like the Cambrian explosion under a molecular clock assumption, poor concurrence between cladistic and phylogenetic data is often observed. There has been some work on models allowing variable rate of evolution. Models that can take into account variability of the rate of the molecular clock between different evolutionary lineages in the phylogeny are called "relaxed" in opposition to "strict". In such models the rate can be assumed to be correlated or not between ancestors and descendants and rate variation among lineages can be drawn from many distributions but usually exponential and lognormal distributions are applied. There is a special case, called "local molecular clock" when a phylogeny is divided into at least two partitions (sets of lineages) and a strict molecular clock is applied in each, but with different rates.
Largely destroyed by the Allies during the Second World War, the city was rebuilt according to the plans of the architect Auguste Perret between 1945 and 1964. Only the City Hall and the Church of Saint Joseph (107-metre high (351 ft)) were personally designed by Auguste Perret. In commending the reconstruction work UNESCO listed the city of Le Havre on 15 July 2005 as a World Heritage Site. This area of 133 hectares (330 acres) is one of the few inscribed contemporary sites in Europe. The architecture of the area is characterized by the use of precast concrete using a system of a modular frame of 6.24 m (20.5 ft) and straight lines. Another notable architectural work of the central city is that of the House of Culture built in 1982 by the Brazilian architect Oscar Niemeyer and nicknamed "the Volcano" because of the shape of the building. From 2012, this place was refurbished both inside and outside with fairly significant changes approved by the architect including greater openness to the outside of the plaza. The Notre Dame and Perrey neighbourhoods are mainly residential. Les Halles is one of the commercial hubs of the city. The Saint Francis neighborhood was also rebuilt beginning in 1950 but in a radically different architectural style: the buildings are brick and have pitched slate roofs. This is the restaurant district and the fish market.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.